Clinical trials: Opioid Withdrawal
Nurse's Role, Stigma, Social
Testing an Arts-based Program to Reduce Nurse Stigma Towards Perinatal Substance Use
The goal of this pilot clinical trial is to evaluate the feasibility and limited effectiveness of a digital, arts-based educational intervention addressing nurse stigma towards perinatal substance use.
- Conditions
- Nurse's Role, Stigma, Social, Implicit Bias
- Trial name
- NCT06410287
- Testing
- ArtSpective
- Where
- 2 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Tobacco Use Disorder
Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers
This study will examine extended exposure to cigarettes varying in nicotine content among adults with opioid use disorder. Those with opioid use disorder are at increased risk for smoking, nicotine dependence, and using high…
- Trial name
- P2S2 (NCT02250664)
- Testing
- Very low nicotine content cigarettes
- Where
- 2 sites in United States
- Volunteers
- 775 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Substance-Related Disorders
Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers
Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped.
- Trial name
- NCT01006707
- Testing
- Ondansetron
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Stanford University
Opioid Withdrawal, Opioid Craving
Oral Cannabidiol for Opioid Withdrawal
This pilot study will examine the safety of the cannabinoid cannabidiol (Epidiolex) in a human laboratory model of clinically relevant withdrawal.
- Conditions
- Opioid Withdrawal, Opioid Craving, Opioid Use Disorder
- Trial name
- NCT04238754
- Testing
- Epidiolex
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Opioid-Related Disorders
Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal
Repeated use and/or abuse of opioid medications is generally associated with a characteristic withdrawal syndrome that develops after cessation of drug administration.
- Trial name
- AV411 (NCT00723177)
- Testing
- AV411
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Opioid-Related Disorders, Opioid Dependence
An Innovative Intervention for OUD Treatment
The Bridge Device (BD) is a neuromodulator medical device that has been cleared by the FDA for Opioid Use Disorder (OUD) treatment.
- Conditions
- Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
- Trial name
- Bridge (NCT04325659)
- Testing
- Bridge Device, Lofexidine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Tobacco Use Disorder
Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Prevalence of smoking among individuals with opioid use disorder (OUD) is six-fold that of the general US adult population. The mortality rate of opioid-dependent smokers is four times that of opioid-dependent nonsmokers, and…
- Trial name
- NCT04092101
- Testing
- Cigarettes with varying nicotine content, E-Cigarettes
- Where
- 2 sites in United States
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Substance-Related Disorders
Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped.
- Trial name
- NCT00661674
- Testing
- Palonosetron, Hydroxyzine
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Substance Withdrawal Syndrome
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
Withdrawal from opioids is a clinical scenario that emergency department physicians encounter frequently. Patients who present with opioid withdrawal display symptoms such as agitation, anxiety, myalgias, abdominal pain…
- Trial name
- NCT02643355
- Testing
- Olanzapine, Clonidine
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hennepin Healthcare Research Institute
Substance Withdrawal Syndrome
Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
Prescription opioid addiction is a growing public health problem and more pharmacologic treatments are needed because current approved medications have had limited patient acceptance (naltrexone), limited availability…
- Trial name
- NCT00980044
- Testing
- Tramadol
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Michelle Lofwall